Transgenomic has appointed Matthew Beer as vice president of business development for oncology; and John McAuliffe as vice president of business development for neurology.
Beer was previously director of oncology marketing and hematology/oncology life cycle leader at Quest Diagnostics. Prior to that, he was vice president of business development at Caris Life Sciences. He has also worked for Abbott, Targeted Molecular Diagnostics, and Oncotech. He holds a BS in microbiology from the University of Iowa.
McAuliffe previously worked at HistoRx, where he served as vice president of sales. Prior to that, he was director of business development at Athena Diagnostics. McAuliffe holds a BS in pharmacolopgy from the University of California, Santa Barbara.
GenMark Diagnostics said this week that Stephen Worland has been appointed to its board of directors.
Worland is currently president and CEO of Effector Therapeutics. He was president and CEO and a director of Anadys Pharmaceuticals from 2007 until the company was acquired by Roche in 2011. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named CEO, including president of pharmaceuticals and chief scientific officer. He began his healthcare industry career in 1988 at Agouron Pharmaceuticals.